INS and cancer: Endogenous hyperinsulinemia, common in type 2 Diabetes due to reduced insulin sensitivity, activates insulin receptors, IGF-1 receptors, and hybrid insulin/IGF-1 receptors, promoting cancer cell proliferation, survival, and metastasis [80].